Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Unit price / market price
-
$0.9539
-
Total 13F principal
-
$713,351,051
-
Principal change
-
+$33,176,169
-
Total reported value
-
$682,649,093
-
Number of holders
-
57
-
Value change
-
+$30,765,855
-
Number of buys
-
21
-
Number of sells
-
26
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q4 2024
As of 31 Dec 2024 HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 had 57 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $713,351,051 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Voya Investment Management LLC, Linden Advisors LP, Wellesley Asset Management, Balyasny Asset Management L.P., LAZARD ASSET MANAGEMENT LLC, BlackRock, Inc., CAMDEN ASSET MANAGEMENT L P /CA, Invesco Ltd., Calamos Advisors LLC, and Opti Capital Management, LP.
This table shows 57 bond principal holders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.